| Literature DB >> 33344907 |
Anna Kletzmayr1, Melina Bigler1, Elita Montanari1, Makoto Kuro-O2, Hirosaka Hayashi2, Mattias E Ivarsson3, Jean-Christophe Leroux1.
Abstract
Kidney calcification increases the risk of chronic kidney disease. However, to date, renal calcium phosphate crystallization, a main initiating and driving factor of kidney calcification, has not been explored as a drug target. Pre-clinical drug development is hampered by limited knowledge on the broad range of kidney calcification disorders, characterized by a multifactorial process of disease progression. In this work, we first established an in vitro calcification profiling platform to accelerate pre-clinical drug discovery. The image-based profiling assay allowed the rapid testing of several ionic stimuli and/or inhibitory molecules. We then leveraged a previously established library of inositol hexakisphosphate analogues to identify a renal calcium phosphate inhibitor. A lead compound showed in vitro and in vivo efficacy to prevent calcium phosphate-induced kidney damage. In conclusion, this work reports a renal calcium phosphate inhibitor that could efficiently reduce kidney damage and emphasizes the utility and translational value of the in vitro calcification platform.Entities:
Year: 2020 PMID: 33344907 PMCID: PMC7737319 DOI: 10.1021/acsptsci.0c00153
Source DB: PubMed Journal: ACS Pharmacol Transl Sci ISSN: 2575-9108